What Is the Treatment for Idiopathic Pericarditis? First-Line Evidence-Based Approach
Acute idiopathic pericarditis is managed with a structured first-line protocol. The approach targets rapid symptom control and normalisation of elevated inflammatory markers, with a clear endpoint that guides tapering decisions.
Treatment overview
Initial management centres on physical rest and activity restriction alongside a combination of a nonsteroidal anti-inflammatory drug (NSAID) and colchicine; gastric protection is incorporated because of the doses involved. Full agent selection, dosing, and the tapering schedule are in the complete protocol.
Complete regimen — including agent options and sequencing — available via the link below.
Treatment targets
- Resolution of symptoms
- Improvement of acutely elevated serum C-reactive protein (CRP)
- Improvement of erythrocyte sedimentation rate (ESR)
- Treatment tapered after an initial 7–14 days once targets are met
References
DOI: 10.1161/CIRCULATIONAHA.111.066365
- It is now common practice to include colchicine, in combination with an NSAID, as initial management of acute idiopathic pericarditis.
- Aspirin and other NSAIDs are the first-line approach, based on clinical experience and observational reports.
- Concurrently, rest and avoidance of demanding physical activity help to minimize symptoms.
- Because high doses are often required, consideration should also be given to gastric protection therapy (eg, a proton pump inhibitor or misoprostol).
- Appropriate therapy for acute idiopathic pericarditis is an NSAID for ≈2 weeks, and it is also reasonable to prescribe colchicine for up to 3 months, especially to reduce the rate of recurrence.
- Commonly used NSAID regimens are listed in the Table, with a recommended initial duration of 7 to 14 days, then treatment should be tapered until resolution of symptoms and improvement of acutely elevated serum inflammatory markers such as C-reactive protein and the erythrocyte sedimentation rate.
View source ↗